Bristol Flying Solo As A Pure Biopharma After Mead Johnson Spin Out
This article was originally published in The Pink Sheet Daily
Executive SummaryDecision to split off the nutritionals unit - Bristol's last diversified business - reflects management's improved confidence in the biopharma business and strength of Mead Johnson's stock price.
You may also be interested in...
The Big Pharma intends to loosen its leash on its former animal health business come June when Pfizer shareholders will be given an option to swap their shares for Zoetis stock. Meanwhile, Pfizer continues its strategy to shift its focus back to the core pharmaceutical business.
Plus news of recent financings by the Pfizer animal health spin-out Zoetis, Bone Therapeutics, Ariad Pharmaceuticals and Foresight Capital Management.
Zoetis makes its debut on the public stock exchange, garnering the highest priced IPO since Facebook began trading last year.